{"success":true,"data":{"pressRelease":{"id":"155907","rtpr_id":"nGNXc6mHsm-20260929","ticker":"LKFT","exchange":"Euronext Amsterdam","all_tickers":["LKFT"],"title":"Acquisition of Own Shares","author":"Globe Newswire","published_at":"2026-09-29T20:01:00.415Z","article_body":"Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated information\n\nWithin the framework of the repurchase program announced on June 9, 2026,\nLakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (\"Lakefront\") announces\nthat between September 21, 2026, and September 25, 2026, it has repurchased\n106,060 Lakefront shares via a discretionary mandate to an independent\nfinancial intermediary, as follows:\n\n Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) \n 21/09/2026 XAMS 19,757 25.24 498,714.10 24.68 25.78 \n 21/09/2026 TQEX 5 25.68 128.40 25.68 25.68 \n 21/09/2026 AQEU 11 24.96 274.56 24.96 24.96 \n 21/09/2026 CEUX 213 24.95 5,313.92 24.82 25.10 \n 22/09/2026 XAMS 17,177 25.99 446,428.51 25.74 26.46 \n 22/09/2026 TQEX 1,523 25.91 39,454.84 25.82 25.96 \n 22/09/2026 AQEU 11 25.82 284.02 25.82 25.82 \n 22/09/2026 CEUX 1,526 26.07 39,782.97 25.82 26.46 \n 23/09/2026 XAMS 18,057 27.56 497,643.70 27.14 28.34 \n 23/09/2026 TQEX 451 27.39 12,355.15 27.30 27.72 \n 23/09/2026 AQEU 5 27.20 136.00 27.20 27.20 \n 23/09/2026 CEUX 1,568 27.55 43,190.87 27.22 28.02 \n 24/09/2026 XAMS 16,754 26.62 445,931.17 26.38 27.02 \n 24/09/2026 TQEX 2,080 26.48 55,082.98 26.44 26.60 \n 24/09/2026 AQEU 8 26.60 212.80 26.60 26.60 \n 24/09/2026 CEUX 3,546 26.73 94,768.98 26.46 26.90 \n 25/09/2026 XAMS 17,446 26.30 458,847.25 25.88 26.62 \n 25/09/2026 TQEX 396 26.54 10,509.60 26.46 26.62 \n 25/09/2026 AQEU 1,585 26.56 42,097.76 26.46 26.62 \n 25/09/2026 CEUX 3,941 26.54 104,583.11 26.00 26.62 \n Total 106,060 26.36 2,795,740.67 24.68 28.34 \n\nAs of market close on September 25, 2026, Lakefront holds 1,633,594 of its own\nordinary shares.\n\nAbout Lakefront Biotherapeutics\nLakefront Biotherapeutics is a biotechnology company dedicated to building a\ndifferentiated pipeline of medicines for patients with serious diseases in\nareas of high unmet need. The Company has established a clinical‑stage\nportfolio in immunology and inflammation, anchored by gamgertamig, a potential\nfirst‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune\ndiseases. Backed by deep deal‑making expertise, operational flexibility, and\na strong capital position, Lakefront identifies, acquires, and advances\nhigh‑quality assets with clear potential to deliver meaningful patient\nimpact and long‑term shareholder value. For more information, visit\nhttps://www.lakefrontbio.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=pHGWx5-APZgUZEVLSgBdFVF5peTeOQ0qs1ZCDxusb259_01ACnG3SV70LQ23pqxnJ0Pc0UWjY2n2ExaJI8s2C3XOBKQZLoGV2EEkt1RXnfmAgWa5Ui8KY0zmwvgPcA54)\nor X\n(https://www.globenewswire.com/Tracker?data=qUjrisx_WIN5uBYWvAstHlWq7ZrWWss_lCBX9BaEIN9_mAWXTdKtrBkRWNU2zzr-Iri3wgy8ovpFaC2unrWulw==).\n\nFor further information, contact Lakefront Biotherapeutics:\nInvestor Relations \nSherri Spear\n+1 412 522 6418\nsherri.spear@lakefrontbio.com\n\nRichie Livingston\n+1 312 636 7072\nrichie.livingston@lakefrontbio.com\n\nForward-looking statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, all of which involve\ncertain risks and uncertainties. These statements are often, but are not\nalways, made through the use of words or phrases such as “believe,”\n“anticipate,” “expect,” “intend,” “plan,” “seek,”\n“upcoming,” “future,” “estimate,” “may,” “will,”\n“could,” “would,” “potential,” “forward,” “goal,”\n“next,” “continue,” “should,” “encouraging,” “aim,”\n“progress,” “remain,” “explore,” and “further,” as well as\nsimilar expressions. These statements include, but are not limited to,\nstatements regarding Lakefront’s plans to repurchase its ordinary shares.\nLakefront cautions the reader that forward-looking statements are based on our\nmanagement’s current expectations and beliefs and are not guarantees of\nfuture performance. Forward-looking statements may involve known and unknown\nrisks, uncertainties and other factors which might cause actual events,\nfinancial condition and liquidity, performance, or achievements, or the\nindustry in which we operate, to be materially different from any historic or\nfuture results, financial conditions, performance or achievements expressed or\nimplied by such forward-looking statements. In addition, even if our results,\nperformance, financial condition and liquidity, and the development of the\nindustry in which Lakefront operates are consistent with such forward-looking\nstatements, they may not be predictive of results or developments in future\nperiods. Such risks include, but are not limited to, those risks and\nuncertainties that can be found in our filings and reports with the Securities\nand Exchange Commission (“SEC”), including in our most recent annual\nreport on Form 20-F filed with the SEC and our subsequent filings and reports\nfiled with the SEC. Given these risks and uncertainties, the reader is advised\nnot to place any undue reliance on such forward-looking statements. In\naddition, even if the result of our operations, financial condition and\nliquidity, or the industry in which we operate, are consistent with such\nforward-looking statements, they may not be predictive of results, performance\nor achievements in future periods. These forward-looking statements speak only\nas of the date of publication of this release. We expressly disclaim any\nobligation to update any such forward-looking statements in this release to\nreflect any change in our expectations or any change in events, conditions or\ncircumstances, unless specifically required by law or regulation.\n\nAttachment\n* 20260925 LakefrontEN RNS Announcement\n(https://ml-eu.globenewswire.com/Resource/Download/d8e946ed-e982-4814-8d90-0506be06ca10)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5100317d-9c26-4bbc-9bcc-dd77343f5f96)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXc6mHsm-20260929","title":"Acquisition of Own Shares","author":"Globe Newswire","ticker":"LKFT","created":"2026-09-29T20:01:00.415Z","tickers":["LKFT"],"exchange":"Euronext Amsterdam","article_body":"Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated information\n\nWithin the framework of the repurchase program announced on June 9, 2026,\nLakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (\"Lakefront\") announces\nthat between September 21, 2026, and September 25, 2026, it has repurchased\n106,060 Lakefront shares via a discretionary mandate to an independent\nfinancial intermediary, as follows:\n\n Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) \n 21/09/2026 XAMS 19,757 25.24 498,714.10 24.68 25.78 \n 21/09/2026 TQEX 5 25.68 128.40 25.68 25.68 \n 21/09/2026 AQEU 11 24.96 274.56 24.96 24.96 \n 21/09/2026 CEUX 213 24.95 5,313.92 24.82 25.10 \n 22/09/2026 XAMS 17,177 25.99 446,428.51 25.74 26.46 \n 22/09/2026 TQEX 1,523 25.91 39,454.84 25.82 25.96 \n 22/09/2026 AQEU 11 25.82 284.02 25.82 25.82 \n 22/09/2026 CEUX 1,526 26.07 39,782.97 25.82 26.46 \n 23/09/2026 XAMS 18,057 27.56 497,643.70 27.14 28.34 \n 23/09/2026 TQEX 451 27.39 12,355.15 27.30 27.72 \n 23/09/2026 AQEU 5 27.20 136.00 27.20 27.20 \n 23/09/2026 CEUX 1,568 27.55 43,190.87 27.22 28.02 \n 24/09/2026 XAMS 16,754 26.62 445,931.17 26.38 27.02 \n 24/09/2026 TQEX 2,080 26.48 55,082.98 26.44 26.60 \n 24/09/2026 AQEU 8 26.60 212.80 26.60 26.60 \n 24/09/2026 CEUX 3,546 26.73 94,768.98 26.46 26.90 \n 25/09/2026 XAMS 17,446 26.30 458,847.25 25.88 26.62 \n 25/09/2026 TQEX 396 26.54 10,509.60 26.46 26.62 \n 25/09/2026 AQEU 1,585 26.56 42,097.76 26.46 26.62 \n 25/09/2026 CEUX 3,941 26.54 104,583.11 26.00 26.62 \n Total 106,060 26.36 2,795,740.67 24.68 28.34 \n\nAs of market close on September 25, 2026, Lakefront holds 1,633,594 of its own\nordinary shares.\n\nAbout Lakefront Biotherapeutics\nLakefront Biotherapeutics is a biotechnology company dedicated to building a\ndifferentiated pipeline of medicines for patients with serious diseases in\nareas of high unmet need. The Company has established a clinical‑stage\nportfolio in immunology and inflammation, anchored by gamgertamig, a potential\nfirst‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune\ndiseases. Backed by deep deal‑making expertise, operational flexibility, and\na strong capital position, Lakefront identifies, acquires, and advances\nhigh‑quality assets with clear potential to deliver meaningful patient\nimpact and long‑term shareholder value. For more information, visit\nhttps://www.lakefrontbio.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=pHGWx5-APZgUZEVLSgBdFVF5peTeOQ0qs1ZCDxusb259_01ACnG3SV70LQ23pqxnJ0Pc0UWjY2n2ExaJI8s2C3XOBKQZLoGV2EEkt1RXnfmAgWa5Ui8KY0zmwvgPcA54)\nor X\n(https://www.globenewswire.com/Tracker?data=qUjrisx_WIN5uBYWvAstHlWq7ZrWWss_lCBX9BaEIN9_mAWXTdKtrBkRWNU2zzr-Iri3wgy8ovpFaC2unrWulw==).\n\nFor further information, contact Lakefront Biotherapeutics:\nInvestor Relations \nSherri Spear\n+1 412 522 6418\nsherri.spear@lakefrontbio.com\n\nRichie Livingston\n+1 312 636 7072\nrichie.livingston@lakefrontbio.com\n\nForward-looking statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, all of which involve\ncertain risks and uncertainties. These statements are often, but are not\nalways, made through the use of words or phrases such as “believe,”\n“anticipate,” “expect,” “intend,” “plan,” “seek,”\n“upcoming,” “future,” “estimate,” “may,” “will,”\n“could,” “would,” “potential,” “forward,” “goal,”\n“next,” “continue,” “should,” “encouraging,” “aim,”\n“progress,” “remain,” “explore,” and “further,” as well as\nsimilar expressions. These statements include, but are not limited to,\nstatements regarding Lakefront’s plans to repurchase its ordinary shares.\nLakefront cautions the reader that forward-looking statements are based on our\nmanagement’s current expectations and beliefs and are not guarantees of\nfuture performance. Forward-looking statements may involve known and unknown\nrisks, uncertainties and other factors which might cause actual events,\nfinancial condition and liquidity, performance, or achievements, or the\nindustry in which we operate, to be materially different from any historic or\nfuture results, financial conditions, performance or achievements expressed or\nimplied by such forward-looking statements. In addition, even if our results,\nperformance, financial condition and liquidity, and the development of the\nindustry in which Lakefront operates are consistent with such forward-looking\nstatements, they may not be predictive of results or developments in future\nperiods. Such risks include, but are not limited to, those risks and\nuncertainties that can be found in our filings and reports with the Securities\nand Exchange Commission (“SEC”), including in our most recent annual\nreport on Form 20-F filed with the SEC and our subsequent filings and reports\nfiled with the SEC. Given these risks and uncertainties, the reader is advised\nnot to place any undue reliance on such forward-looking statements. In\naddition, even if the result of our operations, financial condition and\nliquidity, or the industry in which we operate, are consistent with such\nforward-looking statements, they may not be predictive of results, performance\nor achievements in future periods. These forward-looking statements speak only\nas of the date of publication of this release. We expressly disclaim any\nobligation to update any such forward-looking statements in this release to\nreflect any change in our expectations or any change in events, conditions or\ncircumstances, unless specifically required by law or regulation.\n\nAttachment\n* 20260925 LakefrontEN RNS Announcement\n(https://ml-eu.globenewswire.com/Resource/Download/d8e946ed-e982-4814-8d90-0506be06ca10)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5100317d-9c26-4bbc-9bcc-dd77343f5f96)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T20:01:00.46726113Z","server_sent_at_ms":1790712060467},"received_at":"2026-09-29T20:01:00.517Z","source_url":null},"analysis":{"id":"144621","press_release_id":"155907","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"buyback","narrative":"Lakefront Biotherapeutics repurchased 106,060 of its own shares between September 21 and September 25, 2026, under its June 9, 2026 buyback program.\n\nThe purchases were executed at an average price of €26.36 per share for a total of approximately €2.8 million via a discretionary mandate to an independent financial intermediary.\n\nAs of September 25, 2026, Lakefront holds 1,633,594 of its own ordinary shares in treasury.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine weekly buyback execution under existing program -- low signal."},"keyFigures":{"customDimensions":{"total_spent_eur":2795740.67,"average_price_eur":26.36,"shares_repurchased":106060,"shares_held_treasury":1633594}},"namedEntities":{"people":[{"name":"Sherri Spear","role":"Investor Relations"},{"name":"Richie Livingston","role":"Investor Relations"}],"products":["gamgertamig"],"companies":[{"name":"Lakefront Biotherapeutics NV","ticker":"LKFT","relationship":"filer"}],"dollarAmounts":[{"amount":"€2,795,740.67","context":"total spent repurchasing 106,060 shares Sept 21-25, 2026"}]},"materialImpact":{"score":1,"reasoning":"Routine weekly buyback progress report under an already-announced June 2026 repurchase program. No new authorization or program change."},"tickerRelevance":{"others":[],"primary":"LKFT"},"globalImportance":12,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-buyback-weekly-disclosure","issuerAuthored":true}},"event_type":"buyback","event_type_secondary":null,"sentiment":"bullish","material_impact_score":1,"narrative":"Lakefront Biotherapeutics repurchased 106,060 of its own shares between September 21 and September 25, 2026, under its June 9, 2026 buyback program.\n\nThe purchases were executed at an average price of €26.36 per share for a total of approximately €2.8 million via a discretionary mandate to an independent financial intermediary.\n\nAs of September 25, 2026, Lakefront holds 1,633,594 of its own ordinary shares in treasury.","key_figures":{"customDimensions":{"total_spent_eur":2795740.67,"average_price_eur":26.36,"shares_repurchased":106060,"shares_held_treasury":1633594}},"named_entities":{"people":[{"name":"Sherri Spear","role":"Investor Relations"},{"name":"Richie Livingston","role":"Investor Relations"}],"products":["gamgertamig"],"companies":[{"name":"Lakefront Biotherapeutics NV","ticker":"LKFT","relationship":"filer"}],"dollarAmounts":[{"amount":"€2,795,740.67","context":"total spent repurchasing 106,060 shares Sept 21-25, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T20:01:04.667Z","global_importance":12,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-buyback-weekly-disclosure","issuerAuthored":true}},"durationMs":4126,"modelName":"glm-5.3-flashx"}}